According to the Multiple Sclerosis Foundation, there are approximately 2.5 million people living with multiple sclerosis worldwide.

Multiple Sclerosis (MS) is an autoimmune disorder of the central nervous system. There are four different types of MS, which can be grouped into two categories: symptoms either occur as relapses or build up steadily over time. The most common form is relapsing-remitting multiple sclerosis (RRMS), where new symptoms appear during relapses. When the patient experiences abatement, symptoms can disappear entirely. However, as the disease advances, there are often permanent neurological problems. This disease occurs most frequently between 20-40 years of age and is 2 to 3 times more common in women.1

One of the major challenges MS poses is the simple fact that it is not well understood. It is thought to be the result of a genetic predisposition combined with an environmental or viral factor.


As there are no specific tests for MS, diagnosis can only be made after evaluating damage to the central nervous system and ruling out other possibilities.


Dean, who lives in Queensland, Australia, is 45 and married with two daughters. In 2007, he found out he had multiple sclerosis. Today, thanks to his treatment, he has regained control over his body and can continue enjoying life to the fullest.


Sanophi Genzyme has worked for over a decade to develop new treatments for MS, establishing itself as a leader in providing therapies for the disorder, with two marketed products and several products under development.

While many existing treatments modulate the disease’s symptoms, we are focusing on developing therapies that have the potential to modulate the damaged immune system. We also focus our research on agents that can protect and promote repair of the myelin sheath.

At Sanophi Genzyme, our extensive experience in ultra-rare diseases has shown us that fostering truly personalized medicine is also crucial to effectively treating disorders like MS. We do this by developing relationships with patients and caregivers, healthcare providers and disease organizations and foundations.

We have no doubt that the only way forward is to understand the experiences, challenges and even triumphs of those affected by MS.

“We’re inspired every day by people living MS and the people who care for them, and we’re constantly pushing ourselves to transform what it means to receive an MS diagnosis,” said Bill Sibold, Sanophi Genzyme Franchise Head, Multiple Sclerosis, Oncology and Immunology.

To find out more about our Multiple Sclerosis health solutions, please visit Sanophi Genzyme’s website.


“The patients are our prime source of mobilization and inspiration.” Dr. Christian Deleuze, Sanophi Genzyme, France.

We are a proud partner of important patient organizations working on crucial, large-scale initiatives focused on meeting critical unmet needs in the MS community. Learn more about the programs we support on our website.

In addition to this, Sanophi Genzyme has developed “vs.MS”, a global initiative aimed at uncovering the often unspoken challenges of MS. More specifically, it fielded a global survey among more than 1 500 people living with relapsing MS (RMS) and their care partners across seven countries to encourage behaviour and attitude shifts and drive better, more informed care.

Sanophi Genzyme also developed a seven-week online program, “Spirit: Live a Better Life with MS”, for people living with MS in Norway, Denmark, Sweden and Finland. The program is based on the newest research in health and positive psychology and focuses on inner personal strength. (See / Patient Support Services for more information.)

“You choose to fight MS every morning when you wake up.… Living with MS is living, not giving in.” Melissa, diagnosed with MS 14 years ago.

To find out more about our Multiple Sclerosis health solutions, please visit Sanophi Genzyme’s website.

Latest News

January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.

January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes